Ascendis Pharma Stock Target Price and Analyst Consensus
| ASND Stock | USD 174.88 0.00 0.00% |
The current analyst and expert consensus on Ascendis Pharma is Strong Buy, with 12 strong buy opinions. The current projected Ascendis Pharma target price consensus is 224.52 with 16 analyst opinions. Check out Macroaxis Advice on Ascendis Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. The most common way Ascendis Pharma AS analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Ascendis Pharma executives and customers to further validate their buy or sell advice. Ascendis Pharma buy-or-sell recommendation module provides average expert sentiment on the projected Ascendis Pharma AS target price to derive its highest and lowest estimates based on projected price volatility of 2.3581.
Lowest Forecast 204.32 | Highest Forecast 249.22 | Target Price 224.52 |
It's important to approach Ascendis Pharma's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Ascendis Pharma Target Price Consensus
Ascendis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ascendis Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 16 | Strong Buy |
Most Ascendis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ascendis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ascendis Pharma AS, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAscendis Pharma Target Price Projection
Ascendis Pharma's current and average target prices are 174.88 and 224.52, respectively. The current price of Ascendis Pharma is the price at which Ascendis Pharma AS is currently trading. On the other hand, Ascendis Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Ascendis Pharma Market Quote on 14th of July 2025
Target Price
Analyst Consensus On Ascendis Pharma Target Price
Ascendis Pharma Analyst Ratings
Ascendis Pharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Ascendis Pharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Ascendis Pharma's financials, market performance, and future outlook by experienced professionals. Ascendis Pharma's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Ascendis Pharma price targets
Ascendis Pharma's stock target price is an estimate of its future price, usually made by analysts. Using Ascendis Pharma's target price to determine if it is a suitable investment can be done through the following steps:- Look at Ascendis Pharma's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Ascendis Pharma's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Ascendis Pharma Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Ascendis Pharma is a key component of Ascendis Pharma valuation and have some predictive power on the future returns of a Ascendis Pharma.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | FinTech Invested over 30 shares | |
 | Macroaxis Picks Invested few shares | |
 | Macroaxis Index Invested few shares | |
 | Chemicals Invested over 40 shares | |
 | Automobiles and Trucks Invested over 50 shares | |
 | Hedge Favorites Invested over 100 shares | |
 | Investor Favorites Invested few shares | |
 | Momentum Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Banking Invested over 40 shares | |
Check out Macroaxis Advice on Ascendis Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Please note, the presentation of Ascendis Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ascendis Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ascendis Pharma's management manipulating its earnings.